Curis to Present at Jefferies Virtual Healthcare Conference

Rhea-AI Summary

Curis, a biotechnology company specializing in cancer therapeutics, announced that its CEO, James Dentzer, will participate in a virtual fireside chat at the Jefferies Virtual Healthcare Conference on June 1, 2021, at 3:00 p.m. ET. The event will be available via live webcast on Curis' investor website, with a replay for 90 days post-event. Curis is known for its research in immuno-oncology and precision oncology, including ongoing trials for CA-4948, targeting various forms of cancer.

LEXINGTON, Mass., May 25, 2021 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that announced that James Dentzer, President and Chief Executive Officer of Curis, will participate in a virtual fireside chat at the Jefferies Virtual Healthcare Conference on Tuesday, June 1, 2021 at 3:00 p.m. ET.

A live webcast of the presentation will be available under "Events & Presentations" in the Investors section of the Company's website at www.curis.com. A replay of the webcast will be available on the Curis website for approximately 90 days following the event.

About Curis, Inc.

Curis is a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer. In 2015, Curis entered into a collaboration with Aurigene in the areas of immuno-oncology and precision oncology. As part of this collaboration, Curis has exclusive licenses to oral small molecule antagonists of immune checkpoints including the VISTA/PDL1 antagonist CA-170, and the TIM3/PDL1 antagonist CA-327, as well as the IRAK4 kinase inhibitor, CA-4948. CA-4948 is currently undergoing testing in a Phase 1/2 trial in patients with non-Hodgkin's lymphoma both as a monotherapy and in combination the with BTK inhibitor ibrutinib. Curis is also evaluating CA-4948 in a Phase 1/2 trial in patients with acute myeloid leukemia and myelodysplastic syndromes, for which it has received Orphan Drug Designation from the U.S. Food and Drug Administration. In addition, Curis is engaged in a collaboration with ImmuNext for development of CI-8993, a monoclonal anti-VISTA antibody, which is currently undergoing testing in a Phase 1 trial in patients with solid tumors. Curis is also party to a collaboration with Genentech, a member of the Roche Group, under which Genentech and Roche are commercializing Erivedge^® for the treatment of advanced basal cell carcinoma. For more information, visit Curis' website at www.curis.com.  

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/curis-to-present-at-jefferies-virtual-healthcare-conference-301298430.html

SOURCE Curis, Inc.

FAQ

What is Curis presenting at the Jefferies Virtual Healthcare Conference?

Curis will have its CEO, James Dentzer, participate in a virtual fireside chat on June 1, 2021.

When is the Curis event at the Jefferies Virtual Healthcare Conference?

The event is scheduled for June 1, 2021, at 3:00 p.m. ET.

Where can I watch the Curis presentation from the Jefferies Conference?

The presentation will be available via live webcast on Curis' investor website.

What are the key areas of focus for Curis?

Curis focuses on innovative therapeutics for cancer, particularly in immuno-oncology and precision oncology.

What is the status of Curis' drug CA-4948?

CA-4948 is in ongoing Phase 1/2 trials for non-Hodgkin's lymphoma and acute myeloid leukemia.